Ryan Kitchell oversees a wide variety of business operations at the state’s largest health system. His departure comes as IU Health is in the midst of numerous capital projects.
Responding to a lawsuit by Eli Lilly and two other companies, a federal judge Monday blocked a major White House initiative on prescription drug costs, saying the Trump administration lacked the legal authority to require drugmakers to disclose their prices in TV ads.
The multibillion-dollar merger would combine Elanco, the fourth-largest global player in animal health, with Bayer’s pet-health division, which ranks fifth in veterinary medicine, Reuters reported. The combination would create a dominant force in the industry.
The drug rebate rule would have ended a widespread practice in which drugmakers give rebates to insurance middlemen in government programs such as Medicare. The idea was to channel that money to consumers instead.
In a few days, some of the nation’s most important African American leaders—in business, politics, entertainment and philanthropy—will descend on Indianapolis for the National Urban League Conference.
The Pharmaceutical Research and Manufacturers of America, which represents leading drugmakers including Eli Lilly and Co., reported spending $6.2 million in the quarter. Meanwhile, Lilly boosted its own spending on lobbying.
The Trump administration said Wednesday it will create a pathway allowing Americans to legally and safely import lower-cost prescription drugs from Canada for the first time, reversing years of opposition from federal health authorities.
Not putting all of your economic eggs in one basket has always been sound advice, and over the past couple of decades, U.S. businesses have—slowly—started to apply it. In the 1950s, U.S. exports constituted only 5% of gross domestic product. Today they’re 14%—a record high that’s still rising. Yet the rate is still far below a country like Germany, where exports account for roughly 50% of GDP.
President Donald Trump’s plan to import cheap Canadian drugs overlooks a crucial fact: Canada’s pharmaceutical supply chain is beholden to the drugmakers.
Shah successfully led the merging of Lilly’s information technology, information security, digital health, and advanced analytics and data sciences functions under one umbrella.
Last year, Taltz rang up sales of $937.5 million, and doctors are increasingly prescribing it. For the first six months of this year, Taltz recorded $606.3 million in sales, putting it on pace to break the $1 billion threshold, perhaps in the third quarter.
The new venture, called MBX Biosciences Inc., aims to develop therapeutics to treat rare endocrine disorders. The company has already raised $2.5 million in funding.
Jeff Simmons has been with Greenfield-based Elanco Animal Health for two decades and has run it for 11 years. But he’s never faced pressure like this. Elanco, which was founded in 1954, operated in relative anonymity for most of its existence, serving as a comparatively small division of the publicly traded drug giant Eli Lilly […]
